Workflow
山东药玻(600529) - 2024 Q3 - 季度财报
SPGSPG(SH:600529)2024-10-28 07:35

Financial Performance - The company's operating revenue for Q3 2024 decreased by 0.99% year-on-year, totaling CNY 3,824,950,899.24[2] - Net profit attributable to shareholders increased by 7.23% year-on-year, reaching CNY 720,431,146.66[2] - The basic earnings per share for the period was CNY 1.0856, reflecting a year-on-year increase of 17.29%[2] - Total operating revenue for the first three quarters of 2024 reached CNY 3,824,950,899.24, an increase from CNY 3,673,747,350.74 in the same period of 2023, representing a growth of approximately 4.1%[16] - Net profit for the first three quarters of 2024 was CNY 720,431,146.66, compared to CNY 614,234,124.50 in 2023, reflecting a growth of approximately 17.3%[17] - The total comprehensive income for the third quarter of 2024 reached ¥720,431,146.66, an increase from ¥614,234,124.50 in the same period of 2023, representing a growth of approximately 17.3%[18] Assets and Liabilities - The total assets at the end of the reporting period amounted to CNY 9,979,007,795.90, representing a 7.09% increase compared to the end of the previous year[3] - Total assets as of the end of Q3 2024 amounted to CNY 9,979,007,795.90, up from CNY 9,318,721,550.84 at the end of Q3 2023, showing an increase of approximately 7.1%[15] - Total liabilities increased to CNY 2,191,409,778.84 in 2024 from CNY 1,784,212,772.67 in 2023, representing a growth of about 22.8%[15] - The company's total non-current assets reached CNY 4,033,853,686.34, compared to CNY 3,773,115,590.79 in the previous year, indicating an increase of approximately 6.9%[15] - The total equity attributable to shareholders increased to CNY 7,787,598,017.06 in 2024 from CNY 7,534,508,778.17 in 2023, reflecting a growth of about 3.4%[15] Cash Flow - Cash flow from operating activities for the period was CNY 813,077,771.74, showing an increase of 11.78% year-on-year[2] - Cash inflow from operating activities for the first three quarters of 2024 was ¥3,999,117,010.56, up from ¥3,380,687,417.80 in 2023, indicating a growth of approximately 18.3%[19] - Net cash flow from operating activities for the first three quarters of 2024 was ¥813,077,771.74, compared to ¥727,382,605.46 in 2023, showing an increase of approximately 11.8%[21] - Cash inflow from investment activities was ¥4,781,146,372.42 in the first three quarters of 2024, compared to ¥3,776,990,140.61 in 2023, representing a growth of about 26.5%[21] - Net cash flow from investment activities for the first three quarters of 2024 was -¥914,709,385.13, worsening from -¥773,012,986.54 in 2023[21] Shareholder Information - The number of shareholders holding more than 5% of shares includes Shandong Luzhong Investment Co., Ltd. with 19.50% ownership[10] - The top ten shareholders collectively hold a significant portion of the company's shares, with Shandong Luzhong Investment Co., Ltd. holding 129,380,980 shares[10] - The company reported a total of 54,216,959 shares held by China Bank Co., Ltd. - Huabao CSI Medical ETF, representing 8.17% of total shares[10] - The company has engaged in securities lending activities, with 3,000,000 shares held in a credit securities account by Shandong Luzhong Investment Co., Ltd.[11] Research and Development - The company is focused on expanding its market presence and enhancing its product offerings through ongoing research and development initiatives[12] - Research and development expenses increased to CNY 115,324,642.87 in 2024 from CNY 93,377,102.40 in 2023, marking a rise of about 23.5%[17] Other Financial Metrics - Non-recurring gains and losses for the period totaled CNY 11,422,297.56, with a cumulative amount of CNY 31,417,481.81 for the year-to-date[5] - The company reported a significant increase of 236.16% in asset disposal gains compared to the same period last year[7] - The company experienced a 40.10% increase in trading financial assets year-to-date, attributed to increased purchases of structured bank deposits[6] - The company’s other income increased by 146.92% year-on-year, primarily due to an increase in VAT deductions[7] - Total current assets as of September 30, 2024, amounted to CNY 5,945,154,109.56, an increase from CNY 5,545,605,960.05 as of December 31, 2023, representing a growth of approximately 7.2%[13] - Cash and cash equivalents decreased to CNY 1,087,938,009.78 from CNY 1,466,329,926.87, a decline of about 26%[13] - Inventory increased to CNY 1,206,411,867.83 from CNY 1,054,610,571.71, reflecting a growth of approximately 14.4%[13] - The company's fixed assets rose to CNY 3,473,295,662.24 from CNY 2,994,659,152.84, indicating an increase of around 16%[13] - The total receivables, including notes and accounts, reached CNY 1,770,484,575.04, up from CNY 1,646,346,464.57, marking an increase of about 7.6%[13] - The company's financial expenses showed a decrease, with a net financial cost of -CNY 25,023,212.79 in 2024 compared to -CNY 28,720,110.06 in 2023, indicating improved financial management[17] - Deferred income increased significantly to CNY 110,700,597.67 in 2024 from CNY 57,620,534.05 in 2023, representing an increase of approximately 91.9%[15] - Cash outflow from operating activities totaled ¥3,186,039,238.82 in the first three quarters of 2024, compared to ¥2,653,304,812.34 in 2023, marking an increase of about 20.0%[21] - Cash and cash equivalents at the end of the third quarter of 2024 stood at ¥929,434,878.59, slightly down from ¥934,200,506.87 at the end of the same period in 2023[21] - The company reported tax payments of ¥237,079,540.17 in the third quarter of 2024, compared to ¥204,970,310.22 in 2023, reflecting an increase of approximately 15.6%[21] - The company’s cash inflow from sales of goods and services for the first three quarters of 2024 was ¥3,872,882,678.24, up from ¥3,308,413,735.28 in 2023, indicating a growth of about 17.0%[19]